NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
